Fair 47°
Tag:

Ridgeback Biotherapeutics

News
NJ Company's Experimental COVID Drug Could Be Major Game-Changer NJ Company's Experimental COVID Drug Could Be Major Game-Changer
NJ Company's Experimental COVID Drug Could Be Major Game-Changer New Jersey drug manufacturer Merck & Co. and Ridgeback Biotherapeutics on Friday said the new experimental COVID-19 drug significantly reduces hospitalization time and chance of death for 50 percent of patients with mild to moderate cases. In light of the new findings, the Kenilworth-based company has stopped the drug's trial to apply for emergency use authorization. Molnupiravir is an oral pill and inhibits the replication of the virus inside of the body. “The news of the efficacy of this particular antiviral is obviously very good news,” White House chief medical advisor Dr. Ant…

SHARE

by Cecilia Levine